2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in …
Objective This collaboration between the American College of Rheumatology and the
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
JS Smolen, R Landewé, FC Breedveld… - Annals of the …, 2010 - ard.bmj.com
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …
and consensual international recommendations on RA treatment are not available. In this …
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab …
ML Hetland, IJ Christensen, U Tarp… - … : Official Journal of …, 2010 - Wiley Online Library
Objective To compare tumor necrosis factor α inhibitors directly regarding the rates of
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double …
JS Smolen, J Kay, MK Doyle, R Landewé, EL Matteson… - The Lancet, 2009 - thelancet.com
Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat
rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient …
rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient …
[HTML][HTML] Soluble ligands as drug targets
MM Attwood, J Jonsson, M Rask-Andersen… - Nature Reviews Drug …, 2020 - nature.com
Historically, the main classes of drug targets have been receptors, enzymes, ion channels
and transporters. However, owing largely to the rise of antibody-based therapies in the past …
and transporters. However, owing largely to the rise of antibody-based therapies in the past …
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
JD Greenberg, JM Kremer, JR Curtis… - Annals of the …, 2011 - ard.bmj.com
Objective To examine the association of cardiovascular events with tumour necrosis factor
(TNF) α antagonist use compared with non-biological disease-modifying antirheumatic drug …
(TNF) α antagonist use compared with non-biological disease-modifying antirheumatic drug …
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the …
JL Nam, KL Winthrop, RF van Vollenhoven… - Annals of the …, 2010 - ard.bmj.com
Objectives To review the evidence for the efficacy and safety of biological agents in patients
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Background The biologic disease‐modifying anti‐rheumatic drugs (DMARDs) are very
effective in treating rheumatoid arthritis (RA), however there is a lack of head‐to‐head …
effective in treating rheumatoid arthritis (RA), however there is a lack of head‐to‐head …
The osteoclast: friend or foe?
DV Novack, SL Teitelbaum - Annu. Rev. Pathol. Mech. Dis., 2008 - annualreviews.org
Bone is a dynamic organ constantly remodeled to support calcium homeostasis and
structural needs. The osteoclast is the cell responsible for removing both the organic and …
structural needs. The osteoclast is the cell responsible for removing both the organic and …
Sensing damage by the NLRP3 inflammasome
JC Leemans, SL Cassel… - Immunological reviews, 2011 - Wiley Online Library
The NLRP3 inflammasome is activated in response to a variety of signals that are indicative
of damage to the host including tissue damage, metabolic stress, and infection. Upon …
of damage to the host including tissue damage, metabolic stress, and infection. Upon …